Avalo Therapeutics Inc. (NASDAQ: AVTX) Stock Information | RedChip

Avalo Therapeutics Inc. (NASDAQ: AVTX) Listen to this Section


$9.88
-0.2910 ( -2.86% ) 11.6K

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Market Data


Open


$9.88

Previous close


$10.17

Volume


11.6K

Market cap


$9.62M

Day range


$9.22 - $10.10

52 week range


$3.95 - $71.04

Insider Ownership Transactions

Total Amount Purchased: -1,218,700.00 | $ -12,040,756.00

Date Type Amount Purchased Purchaser
2024-08-14 Sale -24600.00 Truex Samantha
2024-08-14 Sale -500400.00 NEIL GARRY ARTHUR
2024-08-14 Sale -186700.00 Sullivan Christopher Ryan
2024-08-14 Sale -24600.00 KAPLAN GILLA
2024-08-14 Sale -24600.00 Goldman Jonathan
2024-08-14 Sale -24600.00 KANTOFF AARON
2024-08-14 Sale -24600.00 Almenoff June Sherie
2024-08-14 Sale -24600.00 Chan Mitchell
2024-07-16 Sale -234000.00 Doyle Mittie
2024-06-25 Sale -150000.00 VARKI PAUL

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
8-k 8K-related 15 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
10-q Quarterly Reports 71 Aug 12, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.